Table 1 Baseline demographics and clinical characteristics of patients with ulcerative colitis

Female, %

36

60

52

53

47

58

Age at index, years, median (range)

46.5 (18–75)

33.0 (19–76)

35.0 (20–66)

41.0 (22–60)

39.5 (18–75)

34.0 (19–76)

UC duration, years, median (range) [n with available data]^a

5.8 (0–29) [21]

4.2 (0–33) [40]

6.7 (1–47) [54]

6.7 (2–41) [17]

6.1 (0–47) [75]

4.7 (0–41) [57]

UC location, [n]

[21]

[35]

[45]

[12]

[66]

[47]

 Ulcerative proctitis, %

0

9

9

8

6

9

 Left-sided, %

29

40

29

42

29

40

 Extensive colitis, %

10

11

9

17

9

13

 Pancolitis, %

62

40

53

33

56

38

Prior IBD-related surgery, %

5

5

2

0

3

4

Total Mayo score, mean (SD) [n]

5.9 (3.2) [10]

5.7 (2.7) [16]

6.1 (2.8) [27]

7.7 (3.0) [6]

6.0 (2.9) [37]

6.2 (2.9) [22]

Partial Mayo score, mean (SD) [n]

4.8 (2.7) [12]

4.8 (2.5) [18]

4.9 (2.5) [35]

6.9 (2.1) [7]

4.9 (2.6) [47]

5.4 (2.5) [25]

Rectal bleeding score, [n]

[14]

[26]

[44]

[12]

[58]

[38]

 0 (no blood seen), %

36

38

41

25

40

34

 1 (streaks of blood with stool < half of time), %

36

23

30

17

31

21

 2 (obvious blood with stool most of the time), %

14

27

23

25

21

26

 3 (blood alone passes), %

14

12

7

33

9

18

Stool frequency score, [n]

[15]

[23]

[48]

[11]

[63]

[34]

 0 (normal number of stools), %

7

4

17

0

14

3

 1 (1–2 stools/day more than normal), %

33

22

8

0

14

15

 2 (3–4 stools/day more than normal), %

13

22

19

9

17

18

 3 (≥5 stools/day more than normal), %

47

52

56

91

54

65

Endoscopic score, [n]

[12]

[20]

[27]

[8]

[39]

[28]

 0 (normal or inactive disease), %

25

30

11

38

15

32

 1 (mild disease), %

33

35

19

13

23

29

 2 (moderate disease), %

25

25

48

25

41

25

 3 (severe disease), %

17

10

22

25

21

14

Corticosteroids in past 2 years, %

73

68

78

76

76

70

Aminosalicylates in past 2 years, %

86

70

78

71

80

70

Immunomodulators in past 2 years, %

55

58

43

59

46

58

Duration of previous anti-TNFα treatment, months, mean (SD), [n]

–

–

16.8 (16.9) [47]

19.5 (17.0) [16]

16.8 (16.9) [47]

19.5 (17.0) [16]

Duration from prior anti-TNFα discontinuation to index date, months, median (range), [n]

–

–

1.4 (0–32) [50]

1.2 (0–44) [17]

1.4 (0–32) [50]

1.2 (0–44) [17]

 Infliximab originator, %

–

55

–

18

–

44

 Infliximab biosimilar, %

–

15

–

0

–

11

 Adalimumab, %

–

15

–

35

–

21

 Golimumab, %

–

15

–

47

–

25

 Corticosteroids, %

41

50

44

41

43

47

 Immunomodulators, %

23

28

20

35

21

30

 Aminosalicylates, %

59

50

56

53

57

51